Journal List > J Korean Soc Endocrinol > v.20(4) > 1063809

TOOLS
Ryu, Lee, Lee, Koh, Kim, Shin, and Chung: A Case of Drug Induced Nephrogenic Diabetes Insipidus and Hyperprolactinemia in Schizophrenia Simultaneously
Case Report
Journal of Korean Society of Endocrinology

Journal of Korean Society of Endocrinology 2005; 20(4): 407-412.

Published online: 31 August 2005

DOI: https://doi.org/10.3803/jkes.2005.20.4.407

A Case of Drug Induced Nephrogenic Diabetes Insipidus and Hyperprolactinemia in Schizophrenia Simultaneously

Ho Yoel Ryu, Mi Young Lee, Yeon Lee, Jang Hyun Koh, Mi-Jin Kim1, Young Goo Shin, Choon Hee Chung

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wounju, Korea.

1Department of Internal Medicine, Hongik Hospital, Seoul, Korea.

Received 28 January 2005       Accepted 21 June 2005

Copyright © 2005 Korean Endocrine Society

Abstract

In schizophrenia, when treatment using antipsychotics fails, lithium, which is known as an antimanic drug, can also be administered. It is reported that 12~20% of patients taking lithium develop nephrogenic diabetes lactotrophs. Hyperprolactinemia is induced by typical antipsychotics, as they block the dopamine-2 receptors of latotrophs in the pituitary gland. Therefore, atypical antipsychotics for decreasing the side effect, such as hyperprolactinemia, can be used. However, hyperprolactinemia can be induced by risperidone, one of the atypical antipsychotics.
Here, a case of drug induced nephrogenic diabetes insipidus and simultaneous hyperprolactinemia, which occurred in a patient with schizophrenia, is reported.

Keywords: Nephrogenic Diabetes Insipidus, Hyerprolactinemia, Lithium, Risperidone

Figures and Tables

Fig. 1
Sellar MRI Contrst. No gross abnormality.
A. T1 Image coronal view. B. T2 Image coronal view
jkse-20-407-g001
Table 1
Water Deprivation Test and ADH Challenge Test
jkse-20-407-i001

BP: Blood pressure

U/O: Urine output

Urine SG: Urine specific gravity

U,Osm: Urine osmolarity

S,Osm: Urine osmolarity

Table 2
Pituitary Challenge Test
jkse-20-407-i002

References

2. Martin A. Clincal management of lithium-induced polyuria. Hosp Community Psychiatry. Psychiatry. 1993. 44:427–428.
3. Wells BG. Amiloride in lithium-induced polyuria. Ann Pharmacother. 1994. 28:888–889.
4. Molitsh M, Reichlin S. The amenorrhea, galactorrhea and hyperprolactinemia syndrome. Adv Intern Med. 1980. 26:37–65.
5. Marken PA, Haykal RF, Fisher JN. Management of psychotropic-induced hyperprolactinemia. Clin Pharm. 1992. 11:851–856.
6. De Coster R. clinical research report R6476617. Effect of single oral dose administration of rosperidone on plasma prolactin, growth hormone, and cortisol levels in healthy male volunteers. 1988. Beerse, Belgium: Janssen Research Foundation.
7. Alan J, Ellen L, Stephen C. The prationer's guide to psychoactive drug. 1991. 3rd ed. New York: Plenum Medical Company;96–99.
8. Williams WO, Gyory AZ. Aspects of the use of lithium for the non-psychiatrist. Aust N Z J Med. 1976. 6:233–242.
9. Boton R, Gaviria M, Batlle DC. Prevalance, pathogenesis and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 1987. 10:329–345.
10. Passavanti G, Buongiorno E, De Fino G, Rutigliano G, Giannattasio M, Coratelli P. Lithium induced polyuria and polydipsia. Adv Exp Med Biol. 1989. 252:215–231.
11. Zito JM, Sofair JB, Jaeger J. Self-reported neuroendocrine effects of antipsychotics in women: apilot study. DICP. 1990. 24:176–180.
12. Kuruvilla A, Peedicayil J, Srikrishna G, Kuruvilla K, Kanagasabapathy A. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp pharmacil Physiol. 1992. 19:603–606.
13. Gelder Y, De Coster R, Woestenbrorghs C. Clinical Research Report R64766/1. First clinical experience with R64766, a new antipsychotic. 1987. Beerse Belgium: Janssen Research Foundation.
14. Dickson RA, Dalby JT, Williams R, Edward AL. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Am J Psychiatry. 1995. 152:1102–1103.
15. Casey DE. Clozapine: neuroleptic induced EPS and tardive dyskinesia. Psychopharmacology. 1989. 99:Suppl. S47–S53.
16. Philip S, Teresa T. Rapid relaease of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am J Psychiatry. 1999. 156:876–884.
17. Farde L, Nyberg S, Oxentierna G, Nakashima Y, Halldin C, Ericsson B. Position emission tomography studues on D2 and 5HT2 receptor binding in risperidone treated schizoprenic patients. J Clin Psychopharmacology. 1995. 15:Suppl. 19–23.
18. Schiwach RS, Carmody TJ. Prolactogenic effects of risperidone in male patients. Acta Psychiatry Scand. 1998. 98:81–83.
19. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets. 2004. 5:279–299.
20. Guirguis AF, Taylor HC. Nephrogenic diabetes insipidus persisting 57 months after cessation of lithium carbonate therapy: report of a case and review of the literature. Endocr Pract. 2000. 6:324–328.
TOOLS
Similar articles